ziploc_1: From what I've been able to research, it's
not just AMRN and it's SPA. The issue affects all
BioPharm (AMGN,REGN,SNY,PFE etc) and involves all
trials using Lipid Biomarkers as endpoints. The
new policy, as I understand it has to to with a
stipulation in Obama Care that requires "Evidence
Based Medicine" Jan 1 2014. Therefore the Industry
wide change to Outcomes Trials. Apparently, this
requisite will be required for CMS reimbursement.
Timing sucks !